智通财经APP讯，北海康成-B(01228)发布截至2024年12月31日止年度业绩，该集团取得收益8510.3万元，同比减少17.27%;年内亏损4.43亿元，同比增加16.84%;每股亏损1.04元。
公告称，收益减少主要归因于本公司原计划于2021年战略性专注于罕见病，贺俪安®在香港分销的过渡安排于2023年下半年结束。除贺俪安®在香港的销售外，我们的收益较2023年减少580万元或6.4%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.